Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Selective immunosuppression

L Adorini¹, J C Guéry, G Rodriguez-Tarduchy

¹Roche Milano Ricerche, Italy.

Trends in Pharmacological Sciences

|May 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024

Same author

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022

Same author

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

PloS one·2019

Same author

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Journal of endocrinological investigation·2019

Same author

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Journal of endocrinological investigation·2018

Same author

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Biochimica et biophysica acta. Molecular basis of disease·2017

Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026

Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026

Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026

Same journal

Biosensors for translatable GPCR bias.

Trends in pharmacological sciences·2026

Same journal

ECM stiffness and epigenetics in organ fibrosis.

Trends in pharmacological sciences·2026

Same journal

Which HTT transcript to lower?

Trends in pharmacological sciences·2026

See all related articles

Selective immunosuppression targeting antigen-presenting cells, autoreactive T cells, or regulatory T cells can prevent or treat autoimmune diseases. These strategies show promise for human autoimmune disease treatment.

Area of Science:

Immunology
Autoimmune Diseases
Immunosuppression

Background:

Experimental autoimmune disease models show targeted cell interference is effective.
Key cell types include antigen-presenting cells, autoreactive T cells, and regulatory T cells.

Purpose of the Study:

To discuss selective immunosuppression strategies.
To examine applicability to human autoimmune diseases.

Main Methods:

Review of experimental models.
Analysis of selective interference with immune cell activation.

Main Results:

Selective interference with specific immune cells prevents or treats autoimmune disease in models.
Strategies target antigen-presenting cells, autoreactive T cells, and regulatory T cells.

Related Experiment Videos

Conclusions:

Selective immunosuppression is a viable therapeutic approach.
Potential for translation to human autoimmune disease treatment.